46 related articles for article (PubMed ID: 19920456)
1. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial (1).
Kass MA; Gordon MO; Hoff MR; Parkinson JM; Kolker AE; Hart WM; Becker B
J Glaucoma; 1993; 2 Suppl A():1-2. PubMed ID: 19920456
[TBL] [Abstract][Full Text] [Related]
2. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial.
Kass MA
Trans Am Ophthalmol Soc; 1989; 87():598-618. PubMed ID: 2562546
[TBL] [Abstract][Full Text] [Related]
3. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial.
Kass MA; Gordon MO; Hoff MR; Parkinson JM; Kolker AE; Hart WM; Becker B
Arch Ophthalmol; 1989 Nov; 107(11):1590-8. PubMed ID: 2818278
[TBL] [Abstract][Full Text] [Related]
4. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
[TBL] [Abstract][Full Text] [Related]
5. Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension.
Bengtsson B; Heijl A
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2839-42. PubMed ID: 11687526
[TBL] [Abstract][Full Text] [Related]
6. Early treatment study of elevated intraocular pressure (2).
Epstein DL; Krug JH; Hertzmark E; Remis LL; Edelstein DJ
J Glaucoma; 1993; 2 Suppl A():3-4. PubMed ID: 19920458
[TBL] [Abstract][Full Text] [Related]
7. The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study.
Keltner JL; Johnson CA; Anderson DR; Levine RA; Fan J; Cello KE; Quigley HA; Budenz DL; Parrish RK; Kass MA; Gordon MO;
Ophthalmology; 2006 Sep; 113(9):1603-12. PubMed ID: 16949445
[TBL] [Abstract][Full Text] [Related]
8. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
Martínez A; Sánchez M
Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
10. Visual function-specific perimetry for indirect comparison of different ganglion cell populations in glaucoma.
Sample PA; Bosworth CF; Blumenthal EZ; Girkin C; Weinreb RN
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1783-90. PubMed ID: 10845599
[TBL] [Abstract][Full Text] [Related]
11. Results of the European Glaucoma Prevention Study.
Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I;
Ophthalmology; 2005 Mar; 112(3):366-75. PubMed ID: 15745761
[TBL] [Abstract][Full Text] [Related]
12. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle.
Laurence J; Holder D; Vogel R; Gross RL; Haik BG; Karp DW; Koby MM; Zimmerman TJ
J Glaucoma; 1993; 2(3):177-82. PubMed ID: 19920515
[TBL] [Abstract][Full Text] [Related]
13. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
14. Retinal vessel diameter and open-angle glaucoma: the Blue Mountains Eye Study.
Mitchell P; Leung H; Wang JJ; Rochtchina E; Lee AJ; Wong TY; Klein R
Ophthalmology; 2005 Feb; 112(2):245-50. PubMed ID: 15691558
[TBL] [Abstract][Full Text] [Related]
15. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans.
Gandolfi SA; Vecchi M
Invest Ophthalmol Vis Sci; 1996 Mar; 37(4):684-8. PubMed ID: 8595970
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
17. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey.
Ramakrishnan R; Nirmalan PK; Krishnadas R; Thulasiraj RD; Tielsch JM; Katz J; Friedman DS; Robin AL
Ophthalmology; 2003 Aug; 110(8):1484-90. PubMed ID: 12917161
[TBL] [Abstract][Full Text] [Related]
18. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
19. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
20. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
